Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divarasib versus sotorasib or adagrasib in previously treated KRAS G12C-positive advanced or metastatic non-small cell lung cancer
NL-OMON59753Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Sep 2024
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Divarasib with Sotorasib or adagrasib (2 arms). Primary endpoint: Progression-free survival. Started Sep 2024; status: active, not recruiting.
02
Drugs
divarasibsotorasibadagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59753.